Page 3 - Sponsored Level News Today

Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva , an ultra-rare disease with an estimated prevalence of 1.36 per million... | May 26, 2023

Multi-year collaboration will sustain Ipsen’s presence in oncology by leveraging Marengo’s novel discovery of TCR Vβ-targeted precision T cell activation...

INFORMATION RELATING TO THE HOLDING OF THE COMBINED SHAREHOLDERS’ MEETING OF 31 MAY 2023 FORMALITIES FOR MAKING AVAILABLE AND CONSULTINGPREPARATORY...

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance Paris , 27 April 2023Ipsen , a global specialty-driven biopharmaceutical company,... | April 27, 2023

            PRESS RELEASE Regulated Information Ipsen publishes its 2022 Universal Registration Document Paris (France), 6 April...

            PRESS RELEASE Regulated Information Ipsen publishes its 2022 Universal Registration Document Paris , 6 April 2023 – Ipsen... | April 6, 2023

Investegate announcements from Ipsen Pharma, Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP

 Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio Bringing medicines to patients with rare liver...

Investegate announcements from Ipsen Pharma, Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

2022 total sales up by 8.5% at CER1 (14.4% as reported) with growth platforms’2 sales increasing by 20.9%1 and Somatuline® (lanreotide) sales declining by 5.6%1